IrsiCaixa
23
2
5
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.7%
2 terminated/withdrawn out of 23 trials
88.2%
+1.7% vs industry average
17%
4 trials in Phase 3/4
20%
3 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1
Role: collaborator
A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)
Role: collaborator
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment
Role: collaborator
The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events
Role: collaborator
Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
Role: collaborator
Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)
Role: collaborator
LoViReT (Low Viral Reservoir Treated Patients)
Role: lead
A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals
Role: lead
Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals
Role: lead
Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals
Role: lead
Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors
Role: lead
Study to Assess the ART Impact on the Brain Outcomes. The ARBRE Study
Role: collaborator
Viral Clearance and Epidemiological Characteristics in Patients With Monkeypox
Role: collaborator
Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study
Role: collaborator
Immune Therapy and Analytical Treatment Interruption in HIV+ Participants Who Received an Allogeneic Stem Cell Transplantation
Role: lead
Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients
Role: collaborator
Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 (COVID-19) in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%.
Role: collaborator
Professional's Health in Epidemiological Crisis Covid-19
Role: collaborator
Treatment With Immunological Checkpoint Inhibitors of HIV-infected Subjects With Cancer
Role: lead
iHIVARNA Clinical Trial in HIV Infected Individuals
Role: collaborator